H.C. Wainwright reiterated $ATYR Buy-$35-Top Pick after $ATYR announced that the last patient has completed their last visit in the pivotal Phase 3 EFZO-FIT study of lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung

Cantor reiterated $NBIX Overweight/$170. W/ $NBIX reporting 2Q25 next Thurs—Cantor notes volatility around earnings (both⬆️&⬇️; avg 6%), over the last few yrs—but points to the last 3 years, 75% of $NBIX earning prints have seen shares trade higher. $CRNX $BMY $TEVA $PTCT Cantor

H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO, called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in

H.C. Wainwright🏁 $MAZE Buy-$34 and said, "MZE782, a first-in-class SLC6A19 small molecule inhibitor for CKD can be a game changer for the stock, with the Phase 1 PoC data reading out in 3Q 2025. $BMRN $PTCT $CALT $BAYZF H.C. Wainwright added, "Maze's proprietary COMPASS

H.C. Wainwright reiterated $KRRO Buy-$100 and said, "Yesterday, we hosted Korro Bio in the latest episode of our H.C. Wainwright @ Home series." $BEAM $WVE $PRQR $ARWR $IONS $ALNY H.C, Wainwright added, "We have three key takeaways from our discussion: (1) while DNA-editing

H.C. Wainwright reiterated $VKTX Buy-$102 after Viking announced 2Q25 financial results said, "We continue to believe VK2735 is well-positioned within the GLP-1 landscape, across both subcutaneous and oral formulations." $GPCR $LLY $NVO $TERN $AMGN $SRRK Cantor reiterated $VKTX

B. Riley: "We remain buyers of Viking Therapeutics ( $VKTX — Buy, $85 PT) and recommend taking advantage of R&D spend trajectory ($60M actual vs. $45M consensus) related weakness, i.e.,-10% post-close, notably in advance of imminent Ph2 VENTURE-Oral topline data delivering on

📣 Biotech Stock News 07/24 @ Midday $TELO 16% Restores Mitochondrial Health in Cells $IDYA 6% Oral Presentation at ESMO 2025 $ATRA 2% FDA Acceptance and Priority Review for Tabelecleucel $ANNX 2% Completion of Enrollment in ARCHER II Trial $UNCY 2% Publication of Oxylanthanum

Citizens y'day reiterated $GHRS Market Outperform-$39 and said, "Focus remains on ongoing FDA engagement with strong Phase 2b and OLE data reinforcing the blockbuster potential of GH001" $ATAI $JNJ $CMPS $CYBN $MNMD Citizens added, "We reiterate our Market Outperform rating and

Cantor reiterated $JANX Overweight-$200 and said, " $JANX unveiled 3 new early-stage pipeline programs after the close." $JNJ $RHHBY $ABBV $GMAB $VIR $CNTX $MRK $LVTX Cantor added, "In the context of the validation of its masked TCE platform from strong clinical data for

Citi reiterated - Plus Opened a 30-Day Upside Catalyst Watch on $PTCT (Neutral-$50). $BMRN $OTSKY Citi in its note said, "We are not expecting challenges to sepiapterin's approvability for PKU and, in fact, think the rise in $PTCT stock since 1Q earnings (+30% since May 6th) has

Oppenheimer🏁 $WVE Outperform/$24. $KRRO $ALNY $BEAM $ARWR $VRTX $SNY $KMDA Oppenheimer said in its research report: "We initiate Wave Life Sciences ( $WVE) with an Outperform rating and a $24 price target. We view $WVE as a leading innovator in advancing RNA medicine enabled by

H.C. Wainwright assumed coverage on $RARE Buy/$80. $MREO $XBI H.C. Wainwright said, "We are assuming coverage of Ultragenyx Pharmaceuticals with a Buy rating and 12-month price target of $80. In our view, Ultragenyx shares represent an attractive opportunity at current levels,

H.C. Wainwright⬆️ $LENZ PT to $48 from $38 and reiterated at a Buy-2H25 Top Pick after speaking w/ #KOLs ahead of LNZ100's PDUFA (8/8/25). $ABBV H.C. Wainwright said, "Ahead of the near-term August 8, 2025 PDUFA date for $LENZ's novel aceclidine daily eye drop for presbyopia, an

Mizuho⬆️ $ALEC to Outperform-$3.5 from Neutral-$2.5, and additionally⬆️latozinemab PoS to 60% from 50% after #KOL feedback was more +VE than Miz anticipated. $GSK $LLY $TAK $PASG $DNLI $HLBBF Mizuho said in its note to investors: "We upgrade $ALEC to Outperform and raise our PT

Canaccord Genuity⬆️ $CRVO PT to $27 from $21, reit'd Buy & said "The key change we are making is that we are raising our probability of approval estimate from 20% to 33%, which we believe is reasonable based on these encouraging 32-week OLE data." $TEVA $GSK $SNY $ESALF Canaccord

Cantor reiterated $BBIO Overweight-$95 and said, " $BBIO is on a roll, with the launch of Attruby thus far proving doubters wrong." $ALNY $PFE Cantor added, "The company reports on Tuesday, Aug 5th, after the close. While the stock is up >60% YTD, we still think it's just

Cantor reiterated $APLS Overweight/$39 after Apellis announced Empaveli received sNDA approval in patients 12 years or older with C3G or primary IC-MPGN." $NVS $AZN Cantor added, "The label specifically includes eGFR data (showing stability) with a time series insert that's not

Piper Sandler⬆️ $ABVX PT to $112 from $70, reiterated at an Overweight and said "Continue to See Upside Despite the Recent Move; Remain Buyers" $ABBV $SNY - $TEVA $JNJ $MRK Piper Sandler additionally said, "We remain Overweight rated on $ABVX shares, raising our revenue